1. Home
  2. AVXL vs MRVI Comparison

AVXL vs MRVI Comparison

Compare AVXL & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

N/A

Current Price

$3.81

Market Cap

397.6M

Sector

Health Care

ML Signal

N/A

Logo Maravai LifeSciences Holdings Inc.

MRVI

Maravai LifeSciences Holdings Inc.

N/A

Current Price

$3.10

Market Cap

472.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AVXL
MRVI
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.6M
472.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AVXL
MRVI
Price
$3.81
$3.10
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$22.00
$4.57
AVG Volume (30 Days)
1.4M
1.1M
Earning Date
02-09-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$192,435,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.86
$1.67
52 Week High
$13.99
$5.03

Technical Indicators

Market Signals
Indicator
AVXL
MRVI
Relative Strength Index (RSI) 33.16 35.06
Support Level $3.81 $3.07
Resistance Level $5.05 $3.51
Average True Range (ATR) 0.28 0.18
MACD -0.14 -0.08
Stochastic Oscillator 2.58 6.06

Price Performance

Historical Comparison
AVXL
MRVI

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Share on Social Networks: